The world's first malaria vaccine, made by GlaxoSmithKline,
could be approved by international regulators for use in Africa from October
after final trial data showed it offered partial protection for up to four
years.
The shot, called RTS,S and designed for children in Africa,
would be the first licensed human vaccine against a parasitic disease and could
help prevent millions of cases of malaria, which currently kills more than
600,000 people a year, Reuters reports.
Researchers at the British drugmaker GSK have been working
on RTS,S for 30 years.

No comments:
Post a Comment
Kindly drop your comments and also follow
Twitter: @opecareem
Instagram: @opecareem